Cognitive Change Clinical Trial
Official title:
Effects of Single-dose Semaglutide on Cognition and Energy in Healthy Volunteers
Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA). It is a safe medication approved for use in type-2 diabetes mellitus (T2DM) and obesity. Primarily, it works by counteracting insulin-resistance and inducing weight loss. It also acts on several other interconnected neurobiological, immunological (esp. inflammatory), endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms. Its effects on cognition and energy are currently unknown. In this study we are using semaglutide as an experimental tool to further investigate these relationships.
Semaglutide is a novel GLP-1RA licensed for T2DM and obesity, which mainly works by offsetting insulin-resistance and stimulating weight loss (1). It also acts on various neurobiological, immunological, endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms (2). Preliminary evidence suggests these drugs are safe from a neuropsychiatric perspective (3) and could be beneficial in unipolar (4) and bipolar depression (5) - an outcome possibly mediated by inflammatory pathways (6). The proposed study investigates the effects of semaglutide on cognition and energy, which are currently unknown. Work in our laboratory established that short-term use of conventional antidepressants in healthy volunteers shifts reward sensitivity and emotional cognition (7) - an important neuropsychological mechanism of antidepressant action (8). An experimental medicine trial that assesses the effects of semaglutide on reward sensitivity emotional cognition can validate its potential to be repurposed for treating depressive disorders (9). Moreover, brain insulin resistance, likely lessened by semaglutide, is associated with deficit in impulse-control as well as non-emotional cognitive and energy impairment in people with depression (10). Finally, defining the overall cognitive and energy profile of semaglutide is important for the many people already taking it for its licensed indications (i.e., T2DM, obesity). Therefore, the primary objective of this study is to assess the effect of a single dose of semaglutide 0.5mg subcutaneous injection vs placebo on reward sensitivity tasks in healthy volunteers. Secondary objectives include the investigation of the effects of semaglutide on other cognitive domains (emotional processing, impulsivity, memory) and energy/activity levels. Psychological questionnaires are also measured as relevant covariates. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05712005 -
Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
|
||
| Completed |
NCT05343208 -
Effectiveness of Online Therapy to Prevent Burnout
|
N/A | |
| Active, not recruiting |
NCT05143294 -
Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions
|
N/A | |
| Completed |
NCT05267730 -
Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions
|
N/A | |
| Completed |
NCT03987477 -
Online Intervention to Modify Interpretation Biases in Depression
|
N/A | |
| Completed |
NCT03695003 -
Cognitive Effects of Sage in Healthy Humans
|
N/A | |
| Completed |
NCT05075850 -
Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
|
||
| Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
| Completed |
NCT03689348 -
Acute and Chronic Effects of Avena Sativa on Cognition and Stress
|
N/A | |
| Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
| Active, not recruiting |
NCT05229705 -
Exercise in Older Adults at Risk for Type 2 Diabetes
|
N/A | |
| Suspended |
NCT05001789 -
Cognitive Functioning in Opioid Use Disorder
|
N/A | |
| Terminated |
NCT03337282 -
Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
|
||
| Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
| Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
| Completed |
NCT05543811 -
The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology
|
N/A | |
| Recruiting |
NCT05699226 -
Amplitude Titration to Improve ECT Clinical Outcomes
|
N/A | |
| Recruiting |
NCT05026541 -
Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators
|
N/A | |
| Active, not recruiting |
NCT03255499 -
Efficacy of the MovinCog Intervention in Children
|
N/A | |
| Not yet recruiting |
NCT06252376 -
Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD
|
N/A |